Researchers have found a lead compound which they say inhibits SARS-CoV-2 viral replication and demonstrates good pharmacokinetic activity in vivo.
List view / Grid view
Filter the results
A new method has been developed by researchers to create synthetic molecules which replicate natural structures and have potential medicinal uses.
Open innovation – a collaboration between academia and the pharmaceutical industry to further leverage drug discovery expertise and assets
Increasing numbers of companies in the pharma industry are consolidating their services and outsourcing to CROs to reduce business costs. AstraZeneca’s Marian Preston, David Murray and Mark Wigglesworth discuss how this can not only drive innovation but also prove successful in identifying lead compounds, as evidenced through recent collaborations.
A study that identified 12 novel compounds that may prove valuable against new drug targets for leishmaniasis and Chagas disease was not without complication. Here, we discuss the findings but also the challenges the researchers reported in their hit-to-lead study.
Scientists have shared a new method that aims to accelerate the discovery of chemical compounds that inhibit a particular enzyme implicated in several cancers.
Mundipharma EDO GmbH's Dr Thomas Mehrling talks through the benefits of streamlining the drug discovery and development process using the EDO model...
Believed by many to be a relic of past centuries, tuberculosis (TB) causes more deaths than any other infectious disease including HIV/AIDs. In 2015 there were an estimated 10.4 million new cases of TB and 1.4 million deaths from the disease.
Although this target class is already heavily investigated, there are still a significant number of opportunities for discovery of novel drugs targeting additional GPCRs. In this review, scientists from AstraZeneca R&D discuss the general build-up of GPCR screening cascades for discovery of chemical leads that can be further developed into…